We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+13.45%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$3.13B
AUM Growth
+$403M
Cap. Flow
+$107M
Cap. Flow %
3.43%
Top 10 Hldgs %
44.51%
Holding
113
New
15
Increased
22
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
BNTC icon
Benitec Biopharma
BNTC
+$63.9M
2
SBUX icon
Starbucks
SBUX
+$47.2M
3
CRWD icon
CrowdStrike
CRWD
+$34.7M
4
COF icon
Capital One
COF
+$33.5M
5
BIOA
BioAge Labs
BIOA
+$29.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$65.4M
2
ACLX
Arcellx
ACLX
+$55M
3
ELV icon
Elevance Health
ELV
+$49.5M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$46.4M
5
SYY icon
Sysco
SYY
+$37.2M

Sector Composition

Rank Sector Weight
1 Healthcare 53.04%
2 Technology 9.98%
3 Consumer Discretionary 7.64%
4 Communication Services 6.42%
5 Financials 4.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRL icon
101
Charles River Laboratories
CRL
$12.8B
– –
-1,010
Closed -$209K
ELV icon
102
Elevance Health
ELV
$85.5B
– –
-91,442
Closed -$49.5M
FIVE icon
103
Five Below
FIVE
$13.5B
– –
-7,645
Closed -$833K
GILD icon
104
Gilead Sciences
GILD
$165B
– –
-50,700
Closed -$3.48M
HUM icon
105
Humana
HUM
$46.2B
– –
-1,950
Closed -$729K
IMTX icon
106
Immatics
IMTX
$1.32B
– –
-946,563
Closed -$11M
MREO
107
Mereo BioPharma
MREO
$47.3M
– –
-75,000
Closed -$270K
MS icon
108
Morgan Stanley
MS
$340B
– –
-4,611
Closed -$448K
PTGX icon
109
Protagonist Therapeutics
PTGX
$9.44B
– –
-30,500
Closed -$1.06M
SYRE icon
110
Spyre Therapeutics
SYRE
$9.25B
– –
-107,310
Closed -$2.52M
SYY icon
111
Sysco
SYY
$40.3B
– –
-520,900
Closed -$37.2M
TRML
112
DELISTED
Tourmaline Bio
TRML
– –
-125,000
Closed -$1.61M
RVNC
113
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-58,425
Closed -$150K
1 2 3 4
5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Suvretta Capital Management held 113 positions worth $3.13B, up 15% from $2.72B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Suvretta Capital Management deployed $107M of net new capital in Q3 2024, opening 15 new positions and adding to 22 existing holdings. Its largest new stake was Starbucks: 550,309 shares worth $53.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 59% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Insmed, an estimated $65.4M trimmed.

  • Suvretta Capital Management's largest Q3 2024 buy was Starbucks: 550,309 shares worth $53.6M.
  • Suvretta Capital Management added most to Benitec Biopharma in Q3 2024, an estimated $63.9M increase.
  • Suvretta Capital Management's biggest Q3 2024 reduction was Insmed, cutting an estimated $65.4M.
  • Suvretta Capital Management fully exited Elevance Health in Q3 2024, selling an estimated $49.5M.
  • Suvretta Capital Management's ten largest holdings make up 45% of its $3.13B portfolio in Q3 2024.
  • Suvretta Capital Management opened 15 new positions and closed 15 in Q3 2024.
  • Suvretta Capital Management's portfolio value rose 15% quarter-over-quarter to $3.13B.

Based on Suvretta Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.